Previous studies have described that patients with low levels of PD-L1 and tumor-infiltrating lymphocytes (TIL) may derive more benefits from combination therapy, which was designed to enhance T cell infiltration into tumors while concomitantly preventing T cell inactivation [37]. Here, CD274 is linked to neoplasm.